Vertex Pharmaceuticals

Vertex Pharmaceuticals: A Biotech Giant with a Bright Future

Vertex Pharmaceuticals shares jump 6.86% after-hours after Morgan Stanley upgrades to Overweight with $516 price target on kidney drug pipeline.

Morgan Stanley

Morgan Stanley Upgrades Vertex Pharmaceuticals to Overweight on Kidney Pipeline Optimism

福泰制药

Vertex Pharmaceuticals: Morgan Stanley Upgrades Overweight to Equal-Weight, PT Raised to $516.

Eli Lilly

Vanguard Health Care ETF

Vanguard Health Care ETF Insiders Buy Holdings of Eli Lilly and Vertex Pharmaceuticals

Catalyst<ul> <li>Fund flows show positive net inflows across all order sizes including small, medium, large, and extra-large buckets.</li> <li>Fundamental factors indicate strong profitability and growth metrics including ROE, ROA, and gross margin ratio.</li></ul>Risk<ul> <li>Technical indicators show a weak and uncertain market trend with no clear direction in recent periods.</li> <li>Analyst ratings for VRTX show differences in consensus despite a single Buy recommendation from the active analyst.</li></ul>

Key Factors

Morgan Stanley upgrades Vertex Pharmaceuticals to Overweight from Equal-Weight with a raised price target to $516 from $438 citing optimism over its kidney drug pipeline.Vertex Pharmaceuticals shares surge 6.86% after-hours following Morgan Stanley's upgrade to Overweight and a $516 price target based on potential Phase 3 data for kidney drug candidates in 2026.TD Cowen raises Vertex Pharmaceuticals price target to $211 from previous levels citing AI-driven demand acceleration and a $1B cooling acquisition.

Recent Updates

VRTX News